In a recent SEC filing, Sean A. McCarthy, CEO of CytomX Therapeutics, Inc., corrected an inadvertent omission regarding his stock ownership. The filing, dated October 16, 2026, reveals that McCarthy's direct holdings were understated following transactions made on November 6, 2025. This correction is crucial as it provides a more accurate picture of insider ownership at CytomX, a company focused on pharmaceutical preparations.
CytomX Therapeutics, Inc. operates within the pharmaceutical preparations sector, as indicated by its Standard Industrial Classification (SIC) code of 2834. The company is based in South San Francisco, California, and trades under the ticker symbol CTMX. Recent filings show that McCarthy has been actively managing his stock ownership, with multiple transactions reported in 2025 and 2026.
The filing states, "This Form 4/A restates in its entirety the original Form 4 filed on 11/10/2025 to report an inadvertently omitted exercise that was part of a same-day exercise-and-sale transaction." This means that McCarthy exercised options and sold shares on the same day, but the initial report did not include all relevant details, leading to an understatement of his holdings.
Following the correction, McCarthy's direct ownership now reflects an increase of 101,793 shares. He currently holds a total of 1,191,477 shares after the transactions. This update is particularly important for investors and stakeholders who monitor insider trading as it can influence perceptions of the company's stability and leadership.
The correction may affect various stakeholders, including investors, analysts, and other industry players, by ensuring transparency in insider ownership. Accurate reporting is essential for maintaining trust in the market, especially in the pharmaceutical sector where companies are often scrutinized for their governance practices.
The filing does not specify what actions may follow this correction. However, it emphasizes the importance of precise reporting and adherence to regulatory requirements in maintaining investor confidence.